Roche signs a licensing deal with China’s Hansoh for a cancer drug program that several reports say could be worth more than $14 billion, and potentially over $15 billion. Under the agreement, Hansoh receives an upfront payment of $400 million.
The outlets describe the deal in terms of regional rights and later-stage development responsibilities. Hansoh retains rights to the programs in mainland China, Hong Kong, Macau and Taiwan. After completion of early-stage clinical trials, Roche takes responsibility for development and commercialization outside those territories. One source frames the total potential value as exceeding $14 billion, while another and a separate report cite potential deal value above $15 billion.
While the reports do not detail financial triggers, they broadly agree on the headline terms: a large upfront payment to Hansoh, territorial rights split between the two companies, and Roche’s assumption of responsibility for the program outside China’s specified regions following early trial milestones.
